Comparative characteristics of different types of spontaneous HIV-1 non-progressors

Abstract

The aim - to identify and describe different types of spontaneous HIV-1 non-progressors.

Material and methods. We describe the cohort of 31 non-progressors that are under regular medical check-up in Moscow AIDS Center. We identify and characterize 15 elite controllers, 12 HIV controllers and 4 viremic controllers.

Results and discussion. This article provides a brief overview of the interesting and heterogeneous group of patients with long-term control of the HIV-1 replication. We define different variants of HIV-1 non-progression and summarize the main immunologic and genetic characteristics of this group according to the literature. In addition, we discuss the mechanisms underlying HIV-associated cardiovascular disease, including risk factors in patients with long-term spontaneous control of the infection. A better understanding of the mechanisms that underlie virologic control and the long-term clinical outcomes in these groups of patients will be an important step in understanding HIV infection.

Keywords:HIV, elite controllers, HIV controllers, viremic controllers, «non-progressors»

Funding. The study had no sponsor support.

Conflict of interests. The authors declare no conflict of interests.

For citation: Mazus A.I., Tsyganova E.V., Olshansky A.Ya., Heine M.D., Ivannikov E.V., Glukhoedova N.V., Vdovina V.N., Golokhvastova E.L. Comparative characteristics of different types of spontaneous HIV-1 non-progressors. Infektsionnye bolezni: novosti, mneniya, obuchenie [Infectious Diseases: News, Opinions, Training]. 2020; 9 (1): 28-35. doi: 10.33029/2305-3496-2020-9-1-28-35 (in Russian)

References

1. Gonzalo-Gil E., Ikediobi U., Sutton R.E. Mechanisms of virologic control and clinical characteristics of HIV+ elite/viremic controllers. Yale J Biol Med. 2017; 90 (2) 245-59.

2. Gurdasani D.A., Iles L., Dillon D.G., et al. A systematic review of definitions of extreme phenotypes of HIV control and progression the UK HIV Genomics Consortium. AIDS. 2014; 28 (2): 149-62.

3. Grabar S., Selinger-Leneman H., Abgrall S., et al. Loss of long-term non-progressor and HIV controller status over time in the French Hospital Database on HIV - ANRS CO4. PLoS One. 2017; 12 (10): e0184441

4. Okulicz J.F., Marconi V.C., Landrum M.L., et al. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis. 2009; 200 (11): 1714-23.

5. Lambotte O., Boufassa F., Madec Y., et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis. 2005; 41 (7): 1053-6.

6. Grabar S., Selinger-Leneman H., Abgrall S., et al. Prevalence and comparative characteristics of long-term non-progressors and HIV controller patients in the French Hospital Database on HIV. AIDS. 2009; 23 (9): 1163-9.

7. Meijerink H., Indrati A.R., van Crevel R., et al. The number of CCR5 expressing CD4+ T lymphocytes is lower in HIV-infected long-term non-progressors with viral control compared to normal progressors: a cross-sectional study. BMC Infect Dis. 2014; 14: 683.

8. Smith M.W., Dean M., Carrington M., et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science. 1997; 15 (277): 959-65.

9. Yan J., Sabbaj S., Bansal A., et al. HIV-specific CD8+ T cells from elite controllers are primed for survival. J Virol. 2013; 87 (9): 5170-81.

10. Slichter C.K., Friedrich D.P., Smith R.J., et al. Measuring inhibition of HIV replication by ex vivo CD8(+) T cells. J Immunol Methods. 2014; 404: 71-80.

11. Fellay J., Ge D., Shianna K.V., et al. Common genetic variation and the control of HIV-1 in humans. PLoS Genet. 2009; 5 (12): e1000791.

12. MacDonald K.S., Fowke K.R., Kimani J., et al. Influence of HLA supertypes on susceptibility and resistance to human immunodeficiency virus type 1 infection. J Infect Dis. 2000; 181 (5): 1581-9.

13. Santos J.S., Ribeiro C.E., Almeida S.M., et al. Clinical, virologic and immunological outcomes in a cohort of long-term non-progressor HIV infected patients, Southern Brazil. J AIDS Clin Res. 2015; 6 (9). doi: 10.4172/2155-6113.1000502

14. Bosinger S.E., Utay N.S. Type I interferon: understanding its role in HIV pathogenesis and therapy. Curr HIV/AIDS Rep. 2015; 12 (1): 41-53.

15. Palacios J.A., Perez-Pinar T., Toro C., et al. Long-term non-progressor and elite controller patients who control viremia have a higher percentage of methylation in their HIV-1 proviral promoters than aviremic patients receiving highly active antiretroviral therapy. J Virol. 2012; 86 (23): 13 081-4.

16. Nissen S., Christiansen M., Helleberg M., et al. Whole exome sequencing of HIV-1 long-term non-progressors identifies rare variants in genes encoding innate immune sensors and signaling molecules. Sci Rep. 2018; 8 (1): 15253.

17. Brenchley J.M., Price D.A., Schacker T.W., et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006; 12 (12): 1365-71.

18. Acchioni C., Marsili G., Perrotti E., et al. Type I IFN-a blunt spear in fighting HIV-1 infection. Cytokine Growth Factor Rev. 2015; 26 (2): 14358.

19. Freiberg, M. S., Chang C.H., Skanderson M., et al. Association between HIV infection and the risk of heart failure with reduced ejection fraction and preserved ejection fraction in the antiretroviral therapy era: results from the Veterans Aging Cohort Study. JAMA Cardiol. 2017; 2 (5): 536-46.

20. Deeks, S.G., Lewin S.R., Havlir D.V. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013; 382 (9903): 1525-33.

21. D’Ascenzo F., Cerrato E., Calcagno A., et al. High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: a meta-analysis. Atherosclerosis. 2015; 240 (1): 197-204.

22. Hsue P.Y., Waters D.D. Time to recognize HIV infection as a major cardiovascular risk factor. Circulation. 2018; 138 (11): 1113-5.

23. Hsue P.Y., Waters D.D. HIV infection and coronary heart disease: mechanisms and management. Nat Rev Cardiol. 2019; 16 (12): 745-59. doi: 10.1038/s41569-019-0219-9

24. Bartlett J.G., Redfield R.R., Pham P.A., Mazus A.I. Clinical aspects of HIV infection. Moscow: GRANAT, 2013: 696 p. (in Russian)

25. Losina E., Hyle E.P., Borre E.D., et al. Projecting 10-year, 20-year, and lifetime risks of cardiovascular disease in persons living with human immunodeficiency virus in the United States. J Clin Infect Dis. 2017; 65 (8): 1266-71.

26. Post W.S., Budoff M., Kingsley L., et al. Associations between HIV infection and subclinical coronary atherosclerosis: the Multicenter AIDS Cohort Study (MACS). Ann Intern Med. 2014; 160 (7): 458-67.

27. Pereyra F., Lo J., Triant V.A., et al. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. AIDS. 2012; 26 (18): 2409-12.

28. Kearns A., Gordon J., Burdo T.H., Qin X. HIV-1-associated atherosclerosis: unraveling the missing link. J Am Coll Cardiol. 2017; 69 (25): 3084-98.

29. Paiardini M., Mdller-Trutwin M. HIV-associated chronic immune activation. J Immunol Rev. 2013; 254 (1): 78-101.

30. Sauce D., Larsen M., Fastenackels S., et al. HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. Blood. 2011; 117 (19): 5142-51.

31. Longenecker C.T., Sullivan C., Baker J.V. Immune activation and cardiovascular disease in chronic HIV infection. Curr Opin HIV AIDS. 2016; 11 (2): 216-25.

32. Hunt P.W., Brenchley J., Sinclair E., et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis. 2008; 197 (1): 126-33.

33. Crowell T.A., Gebo K.A., Blankson J.N., et al. Hospitalization rates and reasons among HIV elite controllers and persons with medically controlled HIV infection. J Infect Dis. 2015; 211 (11): 1692-702.

34. Zicari S., Sessa L., Cotugno N., et al. Immune activation, inflammation, and non-AIDS co-morbidities in HIV-infected patients under long-term ART. Viruses. 2019; 11 (3). doi: 10.3390/v11030200

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
Aleksandr V. Gorelov
Academician of the Russian Academy of Sciences, MD, Head of Infection Diseases and Epidemiology Department of the Scientific and Educational Institute of Clinical Medicine named after N.A. Semashko ofRussian University of Medicine, Ministry of Health of the Russian Federation, Professor of the Department of Childhood Diseases, Clinical Institute of Children's Health named after N.F. Filatov, Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation, Deputy Director for Research, Central Research Institute of Epidemiology, Rospotrebnadzor (Moscow, Russian Federation)

Journals of «GEOTAR-Media»